Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

49.26  -0.25 (-0.5%)

After market: 49.26 0 (0%)

Fundamental Rating

3

Taking everything into account, EXAS scores 3 out of 10 in our fundamental rating. EXAS was compared to 572 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
In the past year EXAS had a positive cash flow from operations.
In the past 5 years EXAS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M -600M -800M

1.2 Ratios

With an excellent Return On Assets value of -3.17%, EXAS belongs to the best of the industry, outperforming 90.23% of the companies in the same industry.
EXAS's Return On Equity of -6.67% is amongst the best of the industry. EXAS outperforms 91.47% of its industry peers.
Industry RankSector Rank
ROA -3.17%
ROE -6.67%
ROIC N/A
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

Looking at the Gross Margin, with a value of 72.96%, EXAS belongs to the top of the industry, outperforming 84.55% of the companies in the same industry.
EXAS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for EXAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.23, we must say that EXAS is in the distress zone and has some risk of bankruptcy.
EXAS has a better Altman-Z score (1.23) than 68.03% of its industry peers.
EXAS has a debt to FCF ratio of 48.96. This is a negative value and a sign of low solvency as EXAS would need 48.96 years to pay back of all of its debts.
The Debt to FCF ratio of EXAS (48.96) is better than 92.18% of its industry peers.
EXAS has a Debt/Equity ratio of 0.73. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
The Debt to Equity ratio of EXAS (0.73) is worse than 78.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 48.96
Altman-Z 1.23
ROIC/WACCN/A
WACC8.46%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B

2.3 Liquidity

EXAS has a Current Ratio of 2.12. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS has a Current ratio of 2.12. This is in the lower half of the industry: EXAS underperforms 75.31% of its industry peers.
A Quick Ratio of 1.93 indicates that EXAS should not have too much problems paying its short term obligations.
EXAS has a Quick ratio of 1.93. This is in the lower half of the industry: EXAS underperforms 75.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.93
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.79%, which is quite good.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%

3.2 Future

Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.73% on average per year.
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.30% yearly.
EPS Next Y49.15%
EPS Next 2Y53.98%
EPS Next 3Y49.26%
EPS Next 5Y41.73%
Revenue Next Year11.24%
Revenue Next 2Y11.73%
Revenue Next 3Y10.02%
Revenue Next 5Y9.3%

3.3 Evolution

EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EXAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

EXAS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.36% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EXAS is valued cheaply inside the industry as 92.54% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 172.25
EV/EBITDA 1460.18
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as EXAS's earnings are expected to grow with 49.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.98%
EPS Next 3Y49.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (2/21/2025, 8:16:28 PM)

After market: 49.26 0 (0%)

49.26

-0.25 (-0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners100.85%
Inst Owner Change1.04%
Ins Owners0.99%
Ins Owner Change0.57%
Market Cap9.12B
Analysts85.63
Price Target74.16 (50.55%)
Short Float %5.44%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.77%
Min EPS beat(2)0.95%
Max EPS beat(2)72.6%
EPS beat(4)3
Avg EPS beat(4)22.35%
Min EPS beat(4)-26.5%
Max EPS beat(4)72.6%
EPS beat(8)7
Avg EPS beat(8)32.99%
EPS beat(12)10
Avg EPS beat(12)24.85%
EPS beat(16)11
Avg EPS beat(16)-49.56%
Revenue beat(2)0
Avg Revenue beat(2)-1.92%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.37%
Revenue beat(8)3
Avg Revenue beat(8)0.99%
Revenue beat(12)7
Avg Revenue beat(12)1.62%
Revenue beat(16)11
Avg Revenue beat(16)1.79%
PT rev (1m)-0.66%
PT rev (3m)1.61%
EPS NQ rev (1m)8.99%
EPS NQ rev (3m)8.99%
EPS NY rev (1m)2.46%
EPS NY rev (3m)-5.11%
Revenue NQ rev (1m)0.92%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)-0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.39
P/FCF 172.25
P/OCF 39.13
P/B 2.84
P/tB N/A
EV/EBITDA 1460.18
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)0.29
FCFY0.58%
OCF(TTM)1.26
OCFY2.56%
SpS14.55
BVpS17.35
TBVpS-5.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.17%
ROE -6.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.96%
FCFM 1.97%
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 48.96
Debt/EBITDA 332.38
Cap/Depr 83.39%
Cap/Sales 6.69%
Interest Coverage N/A
Cash Conversion 3317.56%
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 1.93
Altman-Z 1.23
F-Score5
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)92.13%
Cap/Depr(5y)182.37%
Cap/Sales(3y)8.75%
Cap/Sales(5y)15.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y49.15%
EPS Next 2Y53.98%
EPS Next 3Y49.26%
EPS Next 5Y41.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
Revenue Next Year11.24%
Revenue Next 2Y11.73%
Revenue Next 3Y10.02%
Revenue Next 5Y9.3%
EBIT growth 1Y20.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year249.76%
EBIT Next 3Y69.11%
EBIT Next 5Y45.97%
FCF growth 1Y110.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.64%
OCF growth 3Y4.58%
OCF growth 5YN/A